Insulet Corporation (NASDAQ:PODD)‘s stock had its “outperform” rating reiterated by investment analysts at Cowen and Company in a research note issued on Friday, The Fly reports. They currently have a $63.00 target price on the medical instruments supplier’s stock, up from their previous target price of $52.00. Cowen and Company’s target price would suggest a potential upside of 17.43% from the stock’s previous close.

A number of other research analysts have also weighed in on PODD. Jefferies Group LLC reissued a “buy” rating and issued a $53.00 target price on shares of Insulet Corporation in a report on Thursday, April 13th. B. Riley reissued a “neutral” rating and issued a $44.00 target price on shares of Insulet Corporation in a report on Tuesday, May 9th. Northland Securities reissued a “buy” rating and issued a $50.00 target price on shares of Insulet Corporation in a report on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $46.00 target price on shares of Insulet Corporation and gave the company a “hold” rating in a report on Tuesday, May 9th. Finally, BTIG Research raised shares of Insulet Corporation from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a report on Wednesday, May 10th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $49.69.

Shares of Insulet Corporation (PODD) traded up 7.11% during midday trading on Friday, hitting $53.65. 963,436 shares of the stock were exchanged. The firm’s 50-day moving average is $50.00 and its 200 day moving average is $44.62. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $55.46. The firm’s market cap is $3.11 billion.

Insulet Corporation (NASDAQ:PODD) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.88%. The firm had revenue of $110 million during the quarter, compared to analyst estimates of $106.23 million. During the same period last year, the firm posted ($0.08) earnings per share. Insulet Corporation’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, analysts forecast that Insulet Corporation will post ($0.48) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Cowen and Company Reiterates Outperform Rating for Insulet Corporation (NASDAQ:PODD)” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/06/cowen-and-company-reiterates-outperform-rating-for-insulet-corporation-nasdaqpodd.html.

In other Insulet Corporation news, SVP Michael P. Spears bought 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was acquired at an average cost of $40.59 per share, for a total transaction of $101,475.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jessica Hopfield bought 2,580 shares of the firm’s stock in a transaction dated Thursday, May 11th. The shares were acquired at an average price of $38.68 per share, with a total value of $99,794.40. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 8,080 shares of company stock valued at $317,339. Corporate insiders own 1.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in PODD. Strs Ohio increased its stake in Insulet Corporation by 73.9% in the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,700 shares during the period. SG Americas Securities LLC acquired a new stake in Insulet Corporation during the second quarter valued at $180,000. Teacher Retirement System of Texas acquired a new stake in Insulet Corporation during the first quarter valued at $201,000. Diversified Trust Co acquired a new stake in Insulet Corporation during the second quarter valued at $205,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in Insulet Corporation during the first quarter valued at $215,000.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

The Fly

Analyst Recommendations for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.